Checkpoint Therapeutics Inc expected to post a loss of 14 cents a share - Earnings Preview

Checkpoint Therapeutics

03/11/2021 10:13

* Checkpoint Therapeutics Inc  CKPT.OQ   CKPT.O  is expected
to show a rise in quarterly revenue when it reports  results on
November 3 (estimated). 
* The New York City, New York-based company is expected to
report  a 328.6% increase in revenue to $120 thousand from $28
thousand a year ago, according to the mean estimate from 5
analysts, based on Refinitiv data. 
​* Refinitiv's mean analyst estimate for Checkpoint Therapeutics
Inc is for a loss of 14 cents per share. For the same quarter
last year, the company reported a loss of 9 cents per share.
* The current average analyst rating on the shares is "buy" and
the breakdown of recommendations is 5 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 
* The mean earnings estimate of analysts was unchanged in the
last three months. ​
* Wall Street's median 12-month price target for Checkpoint
Therapeutics Inc is $17​, about 76.6% above​ its last closing
price of $3.98. ​​​
* Previous quarterly performance (using preferred earnings
measure in US dollars). ​
 QUARTER       STARMINE    REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        SMARTESTIM  IBES                 MET,    SE %
               ATE®        ESTIMATE             MISSED  
 Jun. 302021   -0.10       -0.10      -0.12     Missed  -15.4
 Mar. 312021   -0.11       -0.10      -0.09     Beat    14.3
 Dec. 312020   -0.08       -0.08      -0.17     Missed  -112.5
                                                        ​
 Sep. 302020   -0.08       -0.08      -0.09     Missed  -12.5
 ​​Jun.        -0.09       -0.09      -0.09     Met     0
 302020                                                 
 Mar. 312020   -0.13       -0.13      -0.06     Beat    52.6​
 Dec. 312019   -0.17       -0.17      -0.22     Missed  -32
 Sep. 302019   -0.15       -0.17      -0.15     Beat    10
 This summary was machine generated November 3 at 10:12 GMT.  All
figures in US dollars unless otherwise stated